Current status of adoptive immunotherapy of cancer
- 1 April 1996
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 22 (3) , 213-228
- https://doi.org/10.1016/1040-8428(96)00194-1
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- A novel role for autologous tumour cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanomaSurgical Oncology, 1992
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Preferential Localization of Human Adherent Lymphokine-Activated Killer Cells in Tumor MicrocirculationJNCI Journal of the National Cancer Institute, 1991
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating LymphocytesJNCI Journal of the National Cancer Institute, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985